Short Interest in Ascletis Pharma Inc. (OTCMKTS:ASCLF) Expands By 20.8%

Ascletis Pharma Inc. (OTCMKTS:ASCLF) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 810,726 shares, an increase of 20.8% from the February 26th total of 670,868 shares. Based on an average daily trading volume, of 350 shares, the days-to-cover ratio is currently 2,316.4 days.

Ascletis Pharma Stock Performance

ASCLF opened at $1.81 on Wednesday. The company’s 50-day simple moving average is $1.92 and its two-hundred day simple moving average is $1.65. Ascletis Pharma has a 52-week low of $0.62 and a 52-week high of $2.29.

Ascletis Pharma Company Profile

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).